Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia

International Journal of STD and AIDS

Volumn 16, Issue 11, 2005, Pages 749-754

  Rhodes, Tim ^a   Platt, Lucy ^a   Judd, Ali ^a   Mikhailova, Larissa Albertovna ^b   Sarang, Anya ^a   Wallis, Nigel ^c   Alpatova, Tatiana ^d   Hickman, Matthew ^a   Parry, John V ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b City Narcological Services   (Russian Federation)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d Fifth City Hospital   (Russian Federation)

Author keywords

HCV prevalence; HCV prevention; HIV prevalence; Injecting drug use; Russia

Indexed keywords

HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; DEVICE INFECTION; FEMALE; HEALTH PROMOTION; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MODEL; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RUSSIAN FEDERATION; SELF REPORT; SUPERINFECTION; SYRINGE;

ADULT; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; MALE; PREVALENCE; RISK FACTORS; RUSSIA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 27844491922     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646205774763180     Document Type: Article

References (45)

1. Rhodes T, Sarang A, Bobrik A, Bobkov E, Platt L. HIV transmission HIV prevention associated with injecting drug use in the Russian Federation. Int J Drug Policy 2004;15:1-16
2. Pokrovsky V, Ladnaya N, Sokolova E. HIV epidemic in Russia Eastern Europe: are there any predictors for further heterosexual spreading? 14th International AIDS Conference, Barcelona, Spain, 2002, (abstract: WePeC6077)
3. Rhodes T, Lowndes C, Judd A, et al. Explosive spread high prevalence of HIV infection among injecting drug users in Togliatti City Russian Federation. AIDS 2002;16:F25-32
4. Abdala N, Carney J, Durante A, et al. Estimating the prevalence of syringe-borne sexually transmitted diseases among injectiong drug users in St Petersburg Russia. Int J STD AIDS 2003;14:697-703
5. Smolskaya T, Tretyakova V, Ogurtsova S, et al. Introduction of second generation HIV-surveillance in Russian Federation (Pilot study). Fourth European AIDS Conference, Vilnus, 2002
6. Federal AIDS Centre. HIV Infection: Informational Bulletin No. 26. Moscow: Federal AIDS Centre, 2003
7. UNAIDS. Global AIDS Report. Geneva: UNAIDS, 2003
8. Volkova G, Kutasova T, Kryga L, Ostrovsky D, Boshanov A, Ivanov I. Study of HIV-infection hepatitis B C among drug addicts as a means to improve epidemiological surveillance. Proceedings of Project Participants: Current Problems of HIV AIDS Vol 1. Saint Petersburg, Canadian-Russian, 1999, (AIDS Project 32-34[original in Russian])
9. Sivatcheva I, Trofimov V, Gonchar E, Gorodetskaya I, Lukicheva T. Some results of work of Pskov prevention program among intravenous drug users on limiting the spread of HIV prevention. Proceedings of the Russian National Conference on HIV Blood Borne Viral Hepatitis 1999, (Suzdal 68-702002 [original in Russian])
10. Moshkovich GF, Pikovskaya ED, Fedotova NV, Shilov DV, Kuznetsov AV, Moiseev AP. Prevention of HIV infection other blood-borne diseases among injecting drug users in Nizhny Novgorod associated with harm reduction. Microbiol Epidemiol 2000;4:78-82 (original in Russian)
11. Saukhat S, Tormozova N, Dosyagaeva L, et al. Social-epidemiological monitoring for HIV-infection in Rostov-on-Don. Proceedings of the Russian National Conference on HIV Blood Borne Viral Hepatitis 2002, (Suzdal 71-72 2002 [original in Russian])
12. Balakireva OM, Varban MY. Behavioural practices associated risk among IDUs in Kharkiv Ukraine. XIV International AIDS Conference Barcelona, Spain, 2002, (Abstract: C10767)
13. Garfein RS, Doherty MC, Monterrosso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence incidence of hepatits C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:S11-S19
14. Taylor A, Goldberg D, Hutchinson S, et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect 2000;40:176-83
15. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002;155:645-53
16. MacDonald MA, Wodak AD, Dolan KA, van Beek I, Cunningham PH, Klador JM. Hepatitis C virus antibody prevalence among injecting drug users at selected needle syringe programs in Australia 1995-1997. Med J Australia 2000;172:57-161
17. Des Jarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus hepatitis B virus hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003;157:467-71
18. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States 1988 though 1994. N Engl J Med 1999;341:556-62
19. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange risk of infection with hepatitis B C viruses. Am J Epidemiol 1999;149:203-13
20. Central Eastern European Harm Reduction Network. Injecting Drug Use HIV/AIDS Treatment Primary Care in Central Eastern Europe, the Former Soviet Union. Vilnius, Lithuania: CEEHRN, 2002
21. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behaviour HIV seroconversion among injecting drug users. AIDS 2001;15:1329-41
22. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe exchange programmes. Lancet 1996;348:987-91
23. Hagan H, Thiede H, Weiss N, Hopkins S, Duchin D, Alexander E. Sharing of drug preparation equipment as a risk factor for hepaptitis C. Am J Public Health 2001;91:42-6
24. Goldberg D, Burns S, Taylor A, Cameron S, Hargreaves D, Hutchinson S. Trends in HCV prevalence among injecting drug users in Glasgow Edinburgh during the era of needle/syringe exchange. Scand J Infect Dis 2001;33:457-61
25. Commonwealth Department of Health Ageing. Return on Investment in Needle Syringe Programs in Australia. Canberra: Canberra Commonwealth Department of Health Ageing, 2002
26. Miller CL, Wood E, Spittal PM, et al. The future face of coinfection: prevalence incidence of HIV hepatitis C virus coinfection among young injection drug users. J AIDS 2004;36:743-9
27. Verucchi G, Claza R, Manfredi R, Chiodo F. Human immunodeficiency virus hepatitis C virus coinfection epidemiology natural history therapeutic options clinical management. Infection 2004;33:33-46
28. Rockstroh JK, Spengler U. HIV hepatitis C virus coinfection. Lancet Infect Dis 2004;4:437-44
29. Brau N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions therapy. AIDS 2003;17:2279-90
30. Connell JA, Parry JV, Mortimer PP, Duncan J. Novel assay for the detection of immunoglobulin G anti-human immunodeficiency virus in untreated saliva urine. J Med Virol 1993;1:159-64
31. Connell JA, Parry JV. Detection of anti-HIV in saliva urine at the time of seroconversion. Clin Diagn Virol 1994;1:299-311
32. Judd A, Parry J, Hickman M, et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids dried blood spots. J Med Virol 2003;71:49-55
33. Victora CG, Huttly SR, Fuchs SC, Olinto MT. The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. M J Epidemiol 1997;26:224-7
34. Greub G, Ledergerber B, Battegay M, et al. Clinical progression survival, immune recovery during antiretroviral therapy in patients with HIV-1 hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-5
35. De Luca A, Bugarini R, Cozzi Lepri A, et al. Coinfection with hepatitis viruses outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch Intern Med 2002;162:2125-32
36. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002;16:813-28
37. Sulkowski MS, Moore RD, Metha SH, Chaisson RE, Thomas DL. Hepatitis C progression of HIV disease. JAMA 2002;288:199-206
38. Platt L, Hickman M, Rhodes T, et al. The prevalence of injecting drug use in a Russian city: implications for harm reduction coverage. Addiction 2004;99:1430-8
39. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9
40. Soto B, Sanchez-Quijano A, Rodrigo L, et al. HIV infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5
41. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2002;32:492-7
42. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication liver damage in HIV-coinfected patients on antiretroviral therapy. AIDS 1998;12:116-17
43. World Health Organization. HIV/AIDS Treatment: Antiretroviral Therapy. FACT Sheet EURO/06/03 Copenhagen: WHO, 2003
44. Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 1999;353:1657-61
45. Turner CF, Ku L, Rogers SM, Lindberg LD, Pleck JH, Sonenstein FL. Adolescent sexual behavior drug use, violence: increased reporting with computer survey technology. Science 1998;280:867-73